Discovery and evaluation of Ca v 3.2-selective T-type calcium channel blockers
- 1 December 2017
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (23) , 5326-5331
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Structure–Activity Relationship, Drug Metabolism and Pharmacokinetics Properties Optimization, and in Vivo Studies of New Brain Penetrant Triple T-Type Calcium Channel BlockersJournal of Medicinal Chemistry, 2016
- Preparation, Antiepileptic Activity, and Cardiovascular Safety of Dihydropyrazoles as Brain-Penetrant T-Type Calcium Channel BlockersJournal of Medicinal Chemistry, 2016
- Novel S1P1 Receptor Agonists - Part 2: From Bicyclo[3.1.0]hexane-Fused Thiophenes to Isobutyl Substituted ThiophenesJournal of Medicinal Chemistry, 2013
- Novel S1P1 Receptor Agonists – Part 1: From Pyrazoles to ThiophenesJournal of Medicinal Chemistry, 2013
- Randomized controlled study of the T‐type calcium channel antagonist MK‐8998 for the treatment of acute psychosis in patients with schizophreniaHuman Psychopharmacology: Clinical and Experimental, 2013
- T-Type Calcium Channel Blockers That Attenuate Thalamic Burst Firing and Suppress Absence SeizuresScience Translational Medicine, 2012
- Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike PropertiesACS Chemical Neuroscience, 2010
- The influence of drug-like concepts on decision-making in medicinal chemistryNature Reviews Drug Discovery, 2007
- Inhibition of T-Type and L-Type Calcium Channels by Mibefradil: Physiologic and Pharmacologic Bases of Cardiovascular EffectsJournal of Cardiovascular Pharmacology, 2001
- Nomenclature of Voltage-Gated Calcium ChannelsNeuron, 2000